Molecular testing in lung cancer in the era of precision medicine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283673" target="_blank" >RIV/00179906:_____/14:10283673 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/14:10283673

Výsledek na webu

<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01" target="_blank" >http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.10.01" target="_blank" >10.3978/j.issn.2218-6751.2014.10.01</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Molecular testing in lung cancer in the era of precision medicine

Popis výsledku v původním jazyce

The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs)started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many

Název v anglickém jazyce

Molecular testing in lung cancer in the era of precision medicine

Popis výsledku anglicky

The cliThe clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a separation of small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was sufficient. With the invention of new treatment types a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) role was detected in adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs)started, sub-classification of NSCLC and molecular analysis of the tumor was asked for. Pathologists submit not just a diagnosis, but are involved in a multidisciplinary team for lung cancer management. After EGFR, several other driver genes such as EML4-ALK1, ROS1, DDR2, FGFR1 were discovered, and more will come. Due to new developments in bronchology the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

TLCR Translational lung cancer research

ISSN

2218-6751

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

IN - Indická republika

Počet stran výsledku

10

Strana od-do

291-300

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—